🇺🇸 FDA
Pipeline program

LX1001

LX1001-01

Phase 2 mab completed

Quick answer

LX1001 for Alzheimer Disease is a Phase 2 program (mab) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Alzheimer Disease
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials